Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer.

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...